25 XP   0   0   10

PharmGen Science Inc
Buy, Hold or Sell?

Let's analyse PharmGen Science Inc together

PenkeI guess you are interested in PharmGen Science Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of PharmGen Science Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about PharmGen Science Inc

I send you an email if I find something interesting about PharmGen Science Inc.

Quick analysis of PharmGen Science Inc (30 sec.)










What can you expect buying and holding a share of PharmGen Science Inc? (30 sec.)

How much money do you get?

How much money do you get?
₩0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
₩12,706.22
Expected worth in 1 year
₩17,404.44
How sure are you?
80.0%

+ What do you gain per year?

Total Gains per Share
₩4,698.22
Return On Investment
87.0%

For what price can you sell your share?

Current Price per Share
₩5,400.00
Expected price per share
₩5,070 - ₩5,590
How sure are you?
50%

1. Valuation of PharmGen Science Inc (5 min.)




Live pricePrice per Share (EOD)

₩5,400.00

Intrinsic Value Per Share

₩-5,546.95 - ₩-107.72

Total Value Per Share

₩7,159.27 - ₩12,598.50

2. Growth of PharmGen Science Inc (5 min.)




Is PharmGen Science Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$159.7m$144.9m$14.7m9.2%

How much money is PharmGen Science Inc making?

Current yearPrevious yearGrowGrow %
Making money$4m$49m-$45m-1,123.3%
Net Profit Margin3.4%46.4%--

How much money comes from the company's main activities?

3. Financial Health of PharmGen Science Inc (5 min.)




What can you expect buying and holding a share of PharmGen Science Inc? (5 min.)

Welcome investor! PharmGen Science Inc's management wants to use your money to grow the business. In return you get a share of PharmGen Science Inc.

What can you expect buying and holding a share of PharmGen Science Inc?

First you should know what it really means to hold a share of PharmGen Science Inc. And how you can make/lose money.

Speculation

The Price per Share of PharmGen Science Inc is ₩5,400. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of PharmGen Science Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in PharmGen Science Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩12,706.22. Based on the TTM, the Book Value Change Per Share is ₩1,174.56 per quarter. Based on the YOY, the Book Value Change Per Share is ₩4,464.40 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of PharmGen Science Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.220.0%0.220.0%2.730.1%0.920.0%0.500.0%
Usd Book Value Change Per Share0.820.0%0.820.0%3.130.1%1.340.0%0.800.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.820.0%0.820.0%3.130.1%1.340.0%0.800.0%
Usd Price Per Share4.34-4.34-4.68-5.75-6.26-
Price to Earnings Ratio19.44-19.44-1.71-85.57-63.13-
Price-to-Total Gains Ratio5.28-5.28-1.50--34.34--10.76-
Price to Book Ratio0.49-0.49-0.58-1.40-3.11-
Price-to-Total Gains Ratio5.28-5.28-1.50--34.34--10.76-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.78
Number of shares264
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.821.34
Usd Total Gains Per Share0.821.34
Gains per Quarter (264 shares)217.06352.64
Gains per Year (264 shares)868.231,410.56
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10868858014111401
2017361726028212812
3026052594042324223
4034733462056425634
5043414330070537045
6052095198084638456
7060786066098749867
806946693401128411278
907814780201269512689
1008682867001410614100

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.01.00.090.0%10.02.03.066.7%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%8.02.00.080.0%11.04.00.073.3%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.015.00.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%8.02.00.080.0%11.04.00.073.3%

Fundamentals of PharmGen Science Inc

About PharmGen Science Inc

PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea. It provides prescription drugs, OTC drugs, diagnostic test kits, health and general foods, and cosmetics, as well as shampoo, conditioner, and hair oil products under the neomcell brand name. The company was formerly known as Wooridul Pharmaceutical Limited and changed its name to PharmGen Science, Inc. PharmGen Science, Inc. was founded in 1957 and is headquartered in Hwaseong-si, South Korea.

Fundamental data was last updated by Penke on 2024-04-14 21:15:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is overpriced.

1.1. Profitability of PharmGen Science Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit PharmGen Science Inc earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare PharmGen Science Inc to the Drug Manufacturers - General industry mean.
  • A Net Profit Margin of 3.4% means that ₩0.03 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of PharmGen Science Inc:

  • The MRQ is 3.4%. The company is making a profit. +1
  • The TTM is 3.4%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ3.4%TTM3.4%0.0%
TTM3.4%YOY46.4%-43.0%
TTM3.4%5Y17.9%-14.4%
5Y17.9%10Y9.8%+8.1%
1.1.2. Return on Assets

Shows how efficient PharmGen Science Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare PharmGen Science Inc to the Drug Manufacturers - General industry mean.
  • 1.7% Return on Assets means that PharmGen Science Inc generated ₩0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of PharmGen Science Inc:

  • The MRQ is 1.7%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.7%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.7%TTM1.7%0.0%
TTM1.7%YOY22.1%-20.4%
TTM1.7%5Y9.1%-7.4%
5Y9.1%10Y5.5%+3.6%
1.1.3. Return on Equity

Shows how efficient PharmGen Science Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare PharmGen Science Inc to the Drug Manufacturers - General industry mean.
  • 2.5% Return on Equity means PharmGen Science Inc generated ₩0.03 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of PharmGen Science Inc:

  • The MRQ is 2.5%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 2.5%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ2.5%TTM2.5%0.0%
TTM2.5%YOY33.8%-31.3%
TTM2.5%5Y14.7%-12.2%
5Y14.7%10Y8.4%+6.3%

1.2. Operating Efficiency of PharmGen Science Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient PharmGen Science Inc is operating .

  • Measures how much profit PharmGen Science Inc makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare PharmGen Science Inc to the Drug Manufacturers - General industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of PharmGen Science Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-1.0%+1.0%
5Y-1.0%10Y1.5%-2.5%
1.2.2. Operating Ratio

Measures how efficient PharmGen Science Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • An Operation Ratio of 1.36 means that the operating costs are ₩1.36 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of PharmGen Science Inc:

  • The MRQ is 1.358. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.358. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.358TTM1.3580.000
TTM1.358YOY1.412-0.053
TTM1.3585Y1.434-0.075
5Y1.43410Y1.430+0.004

1.3. Liquidity of PharmGen Science Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if PharmGen Science Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A Current Ratio of 1.51 means the company has ₩1.51 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of PharmGen Science Inc:

  • The MRQ is 1.509. The company is able to pay all its short-term debts. +1
  • The TTM is 1.509. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.509TTM1.5090.000
TTM1.509YOY1.035+0.474
TTM1.5095Y1.457+0.052
5Y1.45710Y2.255-0.798
1.3.2. Quick Ratio

Measures if PharmGen Science Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare PharmGen Science Inc to the Drug Manufacturers - General industry mean.
  • A Quick Ratio of 0.57 means the company can pay off ₩0.57 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of PharmGen Science Inc:

  • The MRQ is 0.572. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.572. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.572TTM0.5720.000
TTM0.572YOY0.419+0.153
TTM0.5725Y0.551+0.021
5Y0.55110Y1.235-0.684

1.4. Solvency of PharmGen Science Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of PharmGen Science Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare PharmGen Science Inc to Drug Manufacturers - General industry mean.
  • A Debt to Asset Ratio of 0.32 means that PharmGen Science Inc assets are financed with 32.1% credit (debt) and the remaining percentage (100% - 32.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of PharmGen Science Inc:

  • The MRQ is 0.321. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.321. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.321TTM0.3210.000
TTM0.321YOY0.347-0.027
TTM0.3215Y0.383-0.062
5Y0.38310Y0.393-0.010
1.4.2. Debt to Equity Ratio

Measures if PharmGen Science Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare PharmGen Science Inc to the Drug Manufacturers - General industry mean.
  • A Debt to Equity ratio of 47.2% means that company has ₩0.47 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of PharmGen Science Inc:

  • The MRQ is 0.472. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.472. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.472TTM0.4720.000
TTM0.472YOY0.532-0.060
TTM0.4725Y0.629-0.157
5Y0.62910Y0.668-0.040

2. Market Valuation of PharmGen Science Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings PharmGen Science Inc generates.

  • Above 15 is considered overpriced but always compare PharmGen Science Inc to the Drug Manufacturers - General industry mean.
  • A PE ratio of 19.44 means the investor is paying ₩19.44 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of PharmGen Science Inc:

  • The EOD is 16.934. Based on the earnings, the company is fair priced.
  • The MRQ is 19.443. Based on the earnings, the company is fair priced.
  • The TTM is 19.443. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD16.934MRQ19.443-2.509
MRQ19.443TTM19.4430.000
TTM19.443YOY1.712+17.731
TTM19.4435Y85.567-66.124
5Y85.56710Y63.128+22.439
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of PharmGen Science Inc:

  • The EOD is 45.168. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 51.860. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is 51.860. Based on how much money comes from the company's main activities, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD45.168MRQ51.860-6.692
MRQ51.860TTM51.8600.000
TTM51.860YOY-9.060+60.920
TTM51.8605Y-12.810+64.670
5Y-12.81010Y155.839-168.650
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of PharmGen Science Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A PB ratio of 0.49 means the investor is paying ₩0.49 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of PharmGen Science Inc:

  • The EOD is 0.425. Based on the equity, the company is cheap. +2
  • The MRQ is 0.488. Based on the equity, the company is cheap. +2
  • The TTM is 0.488. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.425MRQ0.488-0.063
MRQ0.488TTM0.4880.000
TTM0.488YOY0.579-0.091
TTM0.4885Y1.403-0.915
5Y1.40310Y3.107-1.704
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of PharmGen Science Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1174.5551174.5550%4464.402-74%1908.219-38%1137.918+3%
Book Value Per Share--12706.21912706.2190%11531.663+10%7817.949+63%4984.016+155%
Current Ratio--1.5091.5090%1.035+46%1.457+4%2.255-33%
Debt To Asset Ratio--0.3210.3210%0.347-8%0.383-16%0.393-18%
Debt To Equity Ratio--0.4720.4720%0.532-11%0.629-25%0.668-29%
Dividend Per Share----0%-0%-0%-0%
Eps--318.878318.8780%3900.742-92%1311.504-76%709.891-55%
Free Cash Flow Per Share--119.553119.5530%-737.305+717%-494.068+513%-326.117+373%
Free Cash Flow To Equity Per Share--119.553119.5530%-737.305+717%32.886+264%226.978-47%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---107.722--------
Intrinsic Value_10Y_min---5546.946--------
Intrinsic Value_1Y_max---390.756--------
Intrinsic Value_1Y_min---664.907--------
Intrinsic Value_3Y_max---884.490--------
Intrinsic Value_3Y_min---1915.149--------
Intrinsic Value_5Y_max---1029.117--------
Intrinsic Value_5Y_min---3065.253--------
Market Cap96987240000.000-15%111355720000.000111355720000.0000%119976808000.000-7%147456526000.000-24%160621645800.000-31%
Net Profit Margin--0.0340.0340%0.464-93%0.179-81%0.098-65%
Operating Margin----0%-0%-0.0100%0.015-100%
Operating Ratio--1.3581.3580%1.412-4%1.434-5%1.430-5%
Pb Ratio0.425-15%0.4880.4880%0.579-16%1.403-65%3.107-84%
Pe Ratio16.934-15%19.44319.4430%1.712+1035%85.567-77%63.128-69%
Price Per Share5400.000-15%6200.0006200.0000%6680.000-7%8210.000-24%8943.000-31%
Price To Free Cash Flow Ratio45.168-15%51.86051.8600%-9.060+117%-12.810+125%155.839-67%
Price To Total Gains Ratio4.597-15%5.2795.2790%1.496+253%-34.339+751%-10.760+304%
Quick Ratio--0.5720.5720%0.419+37%0.551+4%1.235-54%
Return On Assets--0.0170.0170%0.221-92%0.091-81%0.055-69%
Return On Equity--0.0250.0250%0.338-93%0.147-83%0.084-70%
Total Gains Per Share--1174.5551174.5550%4464.402-74%1908.219-38%1137.918+3%
Usd Book Value--159747917.455159747917.4550%144980915.674+10%98290539.064+63%62661147.728+155%
Usd Book Value Change Per Share--0.8220.8220%3.125-74%1.336-38%0.797+3%
Usd Book Value Per Share--8.8948.8940%8.072+10%5.473+63%3.489+155%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.2230.2230%2.731-92%0.918-76%0.497-55%
Usd Free Cash Flow--1503064.6821503064.6820%-9269704.899+717%-6211634.780+513%-2870056.888+291%
Usd Free Cash Flow Per Share--0.0840.0840%-0.516+717%-0.346+513%-0.228+373%
Usd Free Cash Flow To Equity Per Share--0.0840.0840%-0.516+717%0.023+264%0.159-47%
Usd Market Cap67891068.000-15%77949004.00077949004.0000%83983765.600-7%103219568.200-24%112435152.060-31%
Usd Price Per Share3.780-15%4.3404.3400%4.676-7%5.747-24%6.260-31%
Usd Profit--4009067.1814009067.1810%49041763.428-92%16488782.346-76%8925044.647-55%
Usd Revenue--116745177.955116745177.9550%105651500.759+11%86705862.155+35%67513445.564+73%
Usd Total Gains Per Share--0.8220.8220%3.125-74%1.336-38%0.797+3%
 EOD+4 -4MRQTTM+0 -0YOY+17 -155Y+18 -1410Y+19 -14

3.2. Fundamental Score

Let's check the fundamental score of PharmGen Science Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1516.934
Price to Book Ratio (EOD)Between0-10.425
Net Profit Margin (MRQ)Greater than00.034
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.572
Current Ratio (MRQ)Greater than11.509
Debt to Asset Ratio (MRQ)Less than10.321
Debt to Equity Ratio (MRQ)Less than10.472
Return on Equity (MRQ)Greater than0.150.025
Return on Assets (MRQ)Greater than0.050.017
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of PharmGen Science Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.735
Ma 20Greater thanMa 505,298.000
Ma 50Greater thanMa 1005,568.200
Ma 100Greater thanMa 2005,808.800
OpenGreater thanClose5,400.000
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in KRW. All numbers in thousands.

Summary
Total Assets335,917,099
Total Liabilities107,705,788
Total Stockholder Equity228,221,418
 As reported
Total Liabilities 107,705,788
Total Stockholder Equity+ 228,221,418
Total Assets = 335,917,099

Assets

Total Assets335,917,099
Total Current Assets95,327,309
Long-term Assets240,589,790
Total Current Assets
Cash And Cash Equivalents 36,905,532
Short-term Investments 531,852
Net Receivables 35,616,705
Inventory 20,713,291
Other Current Assets 762,430
Total Current Assets  (as reported)95,327,309
Total Current Assets  (calculated)94,529,810
+/- 797,498
Long-term Assets
Property Plant Equipment 41,272,572
Intangible Assets 6,417,831
Long-term Assets Other 10,605
Long-term Assets  (as reported)240,589,790
Long-term Assets  (calculated)47,701,008
+/- 192,888,782

Liabilities & Shareholders' Equity

Total Current Liabilities63,172,000
Long-term Liabilities44,533,788
Total Stockholder Equity228,221,418
Total Current Liabilities
Short Long Term Debt 37,020,285
Accounts payable 4,867,901
Other Current Liabilities 996,435
Total Current Liabilities  (as reported)63,172,000
Total Current Liabilities  (calculated)42,884,622
+/- 20,287,378
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt943,195
Long-term Liabilities Other 1
Long-term Liabilities  (as reported)44,533,788
Long-term Liabilities  (calculated)943,196
+/- 43,590,592
Total Stockholder Equity
Retained Earnings 130,092,902
Total Stockholder Equity (as reported)228,221,418
Total Stockholder Equity (calculated)130,092,902
+/- 98,128,515
Other
Capital Stock9,001,235
Common Stock Shares Outstanding 17,961
Net Debt 114,753
Net Invested Capital 265,241,703
Net Working Capital 32,155,309
Property Plant and Equipment Gross 59,888,020



Balance Sheet

Currency in KRW. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312005-12-312004-12-312004-09-30
> Total Assets 
49,900,254
49,485,051
66,467,219
42,823,798
42,613,631
39,329,045
42,043,232
46,449,650
64,300,325
68,480,423
98,193,428
100,034,914
135,543,934
220,323,823
317,391,477
335,917,099
335,917,099317,391,477220,323,823135,543,934100,034,91498,193,42868,480,42364,300,32546,449,65042,043,23239,329,04542,613,63142,823,79866,467,21949,485,05149,900,254
   > Total Current Assets 
0
0
0
0
0
30,679,777
33,794,965
38,196,176
53,087,056
55,321,867
80,954,729
50,615,111
74,900,840
77,378,929
70,540,861
95,327,309
95,327,30970,540,86177,378,92974,900,84050,615,11180,954,72955,321,86753,087,05638,196,17633,794,96530,679,77700000
       Cash And Cash Equivalents 
1,358,167
1,150,539
3,038,103
2,178,616
6,026,374
813,151
2,557,184
3,571,243
5,431,129
5,181,301
22,411,985
11,394,382
25,917,020
33,656,122
19,354,593
36,905,532
36,905,53219,354,59333,656,12225,917,02011,394,38222,411,9855,181,3015,431,1293,571,2432,557,184813,1516,026,3742,178,6163,038,1031,150,5391,358,167
       Short-term Investments 
2,268,900
2,433,150
2,753,896
704,038
515,000
1,910,000
3,064,000
5,620,000
17,970,000
16,827,907
23,530,411
4,530,668
4,530,955
531,086
531,283
531,852
531,852531,283531,0864,530,9554,530,66823,530,41116,827,90717,970,0005,620,0003,064,0001,910,000515,000704,0382,753,8962,433,1502,268,900
       Net Receivables 
17,957,450
17,897,331
22,333,584
20,208,056
18,406,638
19,199,517
16,997,360
19,359,479
16,696,074
19,654,236
19,400,098
19,386,482
21,404,052
19,856,779
28,037,445
35,616,705
35,616,70528,037,44519,856,77921,404,05219,386,48219,400,09819,654,23616,696,07419,359,47916,997,36019,199,51718,406,63820,208,05622,333,58417,897,33117,957,450
       Other Current Assets 
301,060
483,966
1,184,236
2,436,284
1,787,784
964,886
1,186,295
896,167
565,298
1,975,655
3,568,297
1,523,409
6,629,160
8,110,231
1,116,916
762,430
762,4301,116,9168,110,2316,629,1601,523,4093,568,2971,975,655565,298896,1671,186,295964,8861,787,7842,436,2841,184,236483,966301,060
   > Long-term Assets 
0
0
0
0
0
0
0
0
11,213,268
13,158,557
17,238,700
49,419,803
60,643,094
142,944,894
246,850,616
240,589,790
240,589,790246,850,616142,944,89460,643,09449,419,80317,238,70013,158,55711,213,26800000000
       Property Plant Equipment 
3,099,589
3,078,494
3,501,358
7,321,719
7,124,824
6,415,451
5,938,748
5,949,874
8,348,152
8,839,475
8,618,300
15,595,267
17,214,389
34,901,624
42,443,807
41,272,572
41,272,57242,443,80734,901,62417,214,38915,595,2678,618,3008,839,4758,348,1525,949,8745,938,7486,415,4517,124,8247,321,7193,501,3583,078,4943,099,589
       Goodwill 
17,141,737
16,237,592
12,621,011
0
53,749
53,749
53,749
53,749
53,749
53,749
53,749
53,749
0
0
0
0
000053,74953,74953,74953,74953,74953,74953,74953,749012,621,01116,237,59217,141,737
       Long Term Investments 
0
0
0
0
0
526,329
703,543
997,342
1,315,708
2,542,274
3,595,641
0
0
0
0
0
000003,595,6412,542,2741,315,708997,342703,543526,32900000
       Intangible Assets 
17,153,871
16,249,073
12,644,900
75,874
681,785
618,808
623,050
582,332
913,876
994,986
1,050,596
991,663
1,936,351
4,434,117
6,177,588
6,417,831
6,417,8316,177,5884,434,1171,936,351991,6631,050,596994,986913,876582,332623,050618,808681,78575,87412,644,90016,249,07317,153,871
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
1
3,198
5,419
4,053
10,605
10,6054,0535,4193,198100000000000
> Total Liabilities 
24,171,159
24,575,473
33,396,940
24,132,351
16,709,724
15,494,661
21,927,091
17,791,291
27,892,704
17,426,086
41,345,912
43,788,770
51,973,965
93,391,563
110,275,883
107,705,788
107,705,788110,275,88393,391,56351,973,96543,788,77041,345,91217,426,08627,892,70417,791,29121,927,09115,494,66116,709,72424,132,35133,396,94024,575,47324,171,159
   > Total Current Liabilities 
22,845,304
22,248,636
26,480,344
21,676,687
13,695,152
12,052,961
17,680,832
12,804,663
21,853,365
10,085,564
32,967,644
30,339,989
37,687,817
71,121,630
68,185,323
63,172,000
63,172,00068,185,32371,121,63037,687,81730,339,98932,967,64410,085,56421,853,36512,804,66317,680,83212,052,96113,695,15221,676,68726,480,34422,248,63622,845,304
       Short-term Debt 
0
0
0
0
0
4,885,712
9,298,069
4,375,518
10,075,890
228,600
19,124,585
17,600,000
0
0
0
0
000017,600,00019,124,585228,60010,075,8904,375,5189,298,0694,885,71200000
       Short Long Term Debt 
0
0
0
0
0
4,885,712
9,298,069
4,375,518
10,075,890
228,600
19,124,585
17,600,000
19,818,237
46,936,536
38,555,425
37,020,285
37,020,28538,555,42546,936,53619,818,23717,600,00019,124,585228,60010,075,8904,375,5189,298,0694,885,71200000
       Accounts payable 
10,244,627
10,103,636
8,264,738
680,723
1,928,185
2,618,250
4,161,372
3,066,920
3,996,409
3,953,625
1,869,191
4,082,054
4,480,323
4,504,713
4,938,467
4,867,901
4,867,9014,938,4674,504,7134,480,3234,082,0541,869,1913,953,6253,996,4093,066,9204,161,3722,618,2501,928,185680,7238,264,73810,103,63610,244,627
       Other Current Liabilities 
4,365,804
3,741,365
4,526,283
8,326,062
4,987,544
4,784,711
4,455,558
4,966,104
6,699,030
5,005,690
9,971,224
5,777,095
10,125,980
15,646,167
1,076,911
996,435
996,4351,076,91115,646,16710,125,9805,777,0959,971,2245,005,6906,699,0304,966,1044,455,5584,784,7114,987,5448,326,0624,526,2833,741,3654,365,804
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
6,039,339
7,340,522
8,378,268
13,448,781
14,286,148
22,269,932
42,090,560
44,533,788
44,533,78842,090,56022,269,93214,286,14813,448,7818,378,2687,340,5226,039,33900000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
-4,885,712
-9,298,069
-4,375,518
-10,075,890
-228,600
-19,124,585
-15,420,486
1,586,543
1,072,682
936,081
943,195
943,195936,0811,072,6821,586,543-15,420,486-19,124,585-228,600-10,075,890-4,375,518-9,298,069-4,885,71200000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
135,631
168,839
355,021
0
1
1
1
1110355,021168,839135,631000000000
       Deferred Long Term Liability 
0
0
0
0
0
218,508
111,158
53,408
114,808
217,091
226,017
203,967
1,582,196
4,026,384
0
0
004,026,3841,582,196203,967226,017217,091114,80853,408111,158218,50800000
> Total Stockholder Equity
25,729,096
24,909,578
33,070,279
18,790,251
25,857,562
23,868,676
20,187,413
28,713,840
36,444,708
50,977,943
56,743,428
56,104,084
83,526,028
126,939,855
207,124,665
228,221,418
228,221,418207,124,665126,939,85583,526,02856,104,08456,743,42850,977,94336,444,70828,713,84020,187,41323,868,67625,857,56218,790,25133,070,27924,909,57825,729,096
   Common Stock
32,150,000
32,150,000
34,068,000
31,788,172
38,600,432
39,736,794
4,073,679
4,713,679
5,027,646
5,644,162
5,785,162
5,843,013
7,356,467
7,616,707
0
0
007,616,7077,356,4675,843,0135,785,1625,644,1625,027,6464,713,6794,073,67939,736,79438,600,43231,788,17234,068,00032,150,00032,150,000
   Retained Earnings Total Equity0000000000000000
   Accumulated Other Comprehensive Income 0000000000000000
   Capital Surplus 0000000000000000
   Treasury Stock000000-587,163-587,163-587,163-587,165-570,237-570,237-570,237000
   Other Stockholders Equity 
0
0
0
0
0
-256,192
-267,385
-268,206
186,056
791,059
-261,245
-1,086,627
-2,754,304
1,436,560
0
0
001,436,560-2,754,304-1,086,627-261,245791,059186,056-268,206-267,385-256,19200000



Balance Sheet

Currency in KRW. All numbers in thousands.




Cash Flow

Currency in KRW. All numbers in thousands.




Income Statement

Currency in KRW. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue166,778,826
Cost of Revenue-68,909,376
Gross Profit97,869,44997,869,449
 
Operating Income (+$)
Gross Profit97,869,449
Operating Expense-157,652,027
Operating Income9,126,798-59,782,578
 
Operating Expense (+$)
Research Development5,118,144
Selling General Administrative61,862,100
Selling And Marketing Expenses-
Operating Expense157,652,02766,980,244
 
Net Interest Income (+$)
Interest Income98,407
Interest Expense-4,263,984
Other Finance Cost-0
Net Interest Income-4,165,577
 
Pretax Income (+$)
Operating Income9,126,798
Net Interest Income-4,165,577
Other Non-Operating Income Expenses-
Income Before Tax (EBT)7,991,2099,126,798
EBIT - interestExpense = -4,263,984
5,727,239
9,991,223
Interest Expense4,263,984
Earnings Before Interest and Taxes (EBIT)-12,255,193
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax7,991,209
Tax Provision-2,265,007
Net Income From Continuing Ops5,726,2025,726,202
Net Income5,727,239
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-4,165,577
 

Technical Analysis of PharmGen Science Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of PharmGen Science Inc. The general trend of PharmGen Science Inc is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine PharmGen Science Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of PharmGen Science Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 5,550 < 5,590 < 5,590.

The bearish price targets are: 5,070.

Tweet this
PharmGen Science Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of PharmGen Science Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

PharmGen Science Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of PharmGen Science Inc. The current macd is -79.94023275.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the PharmGen Science Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for PharmGen Science Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the PharmGen Science Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
PharmGen Science Inc Daily Moving Average Convergence/Divergence (MACD) ChartPharmGen Science Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of PharmGen Science Inc. The current adx is 27.03.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy PharmGen Science Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
PharmGen Science Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of PharmGen Science Inc. The current sar is 5,853.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
PharmGen Science Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of PharmGen Science Inc. The current rsi is 50.73. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
PharmGen Science Inc Daily Relative Strength Index (RSI) ChartPharmGen Science Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of PharmGen Science Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the PharmGen Science Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
PharmGen Science Inc Daily Stochastic Oscillator ChartPharmGen Science Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of PharmGen Science Inc. The current cci is 41.38.

PharmGen Science Inc Daily Commodity Channel Index (CCI) ChartPharmGen Science Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of PharmGen Science Inc. The current cmo is 17.99.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
PharmGen Science Inc Daily Chande Momentum Oscillator (CMO) ChartPharmGen Science Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of PharmGen Science Inc. The current willr is -64.13043478.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that PharmGen Science Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
PharmGen Science Inc Daily Williams %R ChartPharmGen Science Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of PharmGen Science Inc.

PharmGen Science Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of PharmGen Science Inc. The current atr is 153.48.

PharmGen Science Inc Daily Average True Range (ATR) ChartPharmGen Science Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of PharmGen Science Inc. The current obv is 27,947,706.

PharmGen Science Inc Daily On-Balance Volume (OBV) ChartPharmGen Science Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of PharmGen Science Inc. The current mfi is 90.05.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
PharmGen Science Inc Daily Money Flow Index (MFI) ChartPharmGen Science Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for PharmGen Science Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-11MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-12MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-05BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-25CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-16BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-30CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

PharmGen Science Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of PharmGen Science Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.735
Ma 20Greater thanMa 505,298.000
Ma 50Greater thanMa 1005,568.200
Ma 100Greater thanMa 2005,808.800
OpenGreater thanClose5,400.000
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of PharmGen Science Inc with someone you think should read this too:
  • Are you bullish or bearish on PharmGen Science Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about PharmGen Science Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about PharmGen Science Inc

I send you an email if I find something interesting about PharmGen Science Inc.


Comments

How you think about this?

Leave a comment

Stay informed about PharmGen Science Inc.

Receive notifications about PharmGen Science Inc in your mailbox!